Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes

Key Points

• The study aims to evaluate the real-world effectiveness and safety of increasing the semaglutide dose in individuals with type 2 diabetes.
• Conducted a retrospective analysis of clinical data from UMIN-CTR.
• Evaluated responses to escalating doses of semaglutide from 0.5 mg to 1.0 mg.
• Assessed both effectiveness and safety outcomes associated with dosage changes.
• Found improvements in glycemic control with the higher dose of semaglutide.
• Reported a satisfactory safety profile for patients during dosage escalation.

Abstract